ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
ABBOTT LABORATORIES
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 28, 2026
$104.06−0.83 (-0.79%)
Close on Oct 19, 2026
- Market cap
- $181.80B
- P/E (TTM)
- 29.0
- Dividend yield
- 2.31%
Abbott Laboratories statistics
Financials through Mar 31, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Abbott Laboratories | Industry median |
|---|---|---|
| Market Cap | $180.06B | $166.30M |
| Enterprise Value | $207.46B | $87.12M |
| PE Ratio | 28.99 | 19.67 |
| PS Ratio | 3.99 | 3.60 |
| PB Ratio | 3.46 | 2.03 |
| P/FCF Ratio | 24.41 | 17.44 |
| P/OCF Ratio | 19.03 | 13.32 |
Enterprise value
| Measure | Abbott Laboratories | Industry median |
|---|---|---|
| EV / Sales | 4.60 | 2.43 |
| EV / EBITDA | 26.92 | 14.69 |
| EV / EBIT | 26.92 | 18.47 |
| EV / FCF | 28.12 | 20.97 |
Income (trailing twelve months)
| Measure | Abbott Laboratories | Industry median |
|---|---|---|
| Revenue | $45.13B | $57.94M |
| Gross Profit | $25.39B | $90.47M |
| Operating Income | $7.71B | -$21.49M |
| Pretax Income | $8.14B | -$14.72M |
| Net Income | $6.28B | -$22.46M |
| EBITDA | $7.71B | -$17.14M |
| EPS (Diluted) | $3.59 | -$0.83 |
Margins
| Measure | Abbott Laboratories | Industry median |
|---|---|---|
| Gross Margin | 56.3% | 52.3% |
| Operating Margin | 17.1% | -44.5% |
| Pretax Margin | 18.0% | -13.0% |
| Profit Margin | 13.9% | -39.2% |
| EBITDA Margin | 17.1% | -31.3% |
| FCF Margin | 16.3% | -8.85% |
Returns
| Measure | Abbott Laboratories | Industry median |
|---|---|---|
| Return on Equity (ROE) | 12.4% | -53.2% |
| Return on Assets (ROA) | 6.54% | -41.0% |
| Return on Invested Capital (ROIC) | 8.87% | -32.2% |
| Return on Capital Employed (ROCE) | 8.37% | -38.0% |
Growth
| Measure | Abbott Laboratories | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 6.59% | 6.01% |
| Net Income Growth (YoY) | -53.5% | -37.7% |
| EPS Growth (YoY) | -53.5% | -29.2% |
| FCF Growth (YoY) | 10.8% | 2.34% |
| Revenue Growth (3Y CAGR) | 0.51% | 2.25% |
| Revenue Growth (5Y CAGR) | 5.08% | 6.42% |
| EPS Growth (3Y CAGR) | -1.65% | -0.17% |
| EPS Growth (5Y CAGR) | 8.27% | 3.77% |
Balance sheet
| Measure | Abbott Laboratories | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $7.30B | $62.64M |
| Total Debt | $34.05B | $120.13M |
| Net Cash (Debt) | -$26.75B | $15.77M |
| Net Cash Per Share | -$15.46 | $0.66 |
| Equity (Book Value) | $52.06B | $48.61M |
| Book Value Per Share | $30.09 | $1.36 |
| Tangible Book Value | -$1.04B | $23.01M |
| Working Capital | $7.13B | $75.09M |
Financial position
| Measure | Abbott Laboratories | Industry median |
|---|---|---|
| Current Ratio | 1.39 | 3.30 |
| Quick Ratio | 0.84 | 2.39 |
| Debt / Equity | 0.65 | 0.51 |
| Debt / EBITDA | 4.42 | 3.35 |
| Debt / FCF | 4.61 | 5.05 |
| Net Debt / EBITDA | 3.47 | 2.22 |
| Interest Coverage | 14.38 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Abbott Laboratories | Industry median |
|---|---|---|
| Operating Cash Flow | $9.46B | -$12.39M |
| Capital Expenditures | -$2.09B | -$1.07M |
| Free Cash Flow | $7.38B | -$20.34M |
| FCF Per Share | $4.26 | -$0.42 |
Efficiency
| Measure | Abbott Laboratories | Industry median |
|---|---|---|
| Asset Turnover | 0.47 | 0.38 |
| Inventory Turnover | 2.90 | 2.67 |
| Revenue Per Employee | $392.47K | $398.96K |
| Profits Per Employee | $54.57K | -$705.27K |
| Employee Count | 115,000 | 74 |
Dividends and yields
| Measure | Abbott Laboratories | Industry median |
|---|---|---|
| Earnings Yield | 3.49% | -22.8% |
| FCF Yield | 4.10% | -9.02% |
| Dividend Yield | 2.31% | 1.82% |
| Buyback Yield | 0.44% | -0.73% |
| Shareholder Yield | 2.75% | 0.00% |
| Dividend Per Share | $2.40 | $0.83 |
| Dividend Growth (YoY) | 7.14% | 2.37% |
| Years of Dividend Growth | 3 | 0 |
| Payout Ratio | 66.7% | 47.7% |
| FCF Payout Ratio | 56.8% | 51.6% |
Shares
| Measure | Abbott Laboratories | Industry median |
|---|---|---|
| Shares Outstanding | 1,730,380,000 | 58,139,000 |
| Shares Change (YoY) | 0.03% | 11.1% |
| Float | 1,721,810,000 | 49,154,900 |
| Shares Held by Insiders | 0.50% | 11.6% |
| Shares Held by Institutions | 79.8% | 59.4% |
Taxes
| Measure | Abbott Laboratories | Industry median |
|---|---|---|
| Income Tax | $1.86B | $89.00K |
| Effective Tax Rate | 22.9% | 20.5% |
Scores
| Measure | Abbott Laboratories | Industry median |
|---|---|---|
| Graham Number | $49.30 | $17.04 |
| Graham Upside | -52.6% | -44.3% |
| Altman Z-Score | 3.22 | -0.27 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from Abbott Laboratories's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.